Air Max Day, celebrated annually on March 26, commemorates the debut of Nike's revolutionary Air Max 1 sneaker — which dates ...

Wealth host Madison Mills explores several trending stocks this morning: Novo Nordisk (NVO ... The new MacBook Air will get the company's M4 chip and will actually cost $100 less than it did ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly ...

Less than two weeks after Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk said Wednesday it would cut the price of its popular weight-loss drug Wegovy ...

This is centered on its hotly popular drug Wegovy. Before market open, Novo Nordisk announced the launch of its NovoCare Pharmacy, a direct-to-patient delivery service for its best-selling Wegovy ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

The early bird gets the worm. Or, in this case, it's the early adopter who gets the "insanely comfortable" shoes. Nike's ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

As one of the few “small-batch” road shoe makers, how does a more-advanced Atreyu's Daily Trainer 2.0 stack up?